The Oncology Institute, Inc. TOI
At closeAug 3, 2026, 4:00 PM EDT
After hours · Aug 3, 4:00 PM ET
52-week range unavailable
- YTD
- +44.10%
- 1 year
- +129.02%
- Market cap
- 15.42M
- Revenue (ttm)
- 361.07M
- Profit margin
- -19.81%
- Shares out
- 75.56M
- Forward P/E
- -1.28
- YTD return
- +44.10%
- 1-year return
- +129.02%
- Volume
- 1.21M
- Open
- 4.94
- Previous close
- 5.13
- Day's range
- 4.87 – 5.15
- Beta
- 0.62
Key statistics
- Enterprise value
- 92.40M
- PEG ratio
- 0.00
- Price / sales
- 0.04
- Price / book
- 0.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 22.90%
- Free cash flow
- -23.95M
- Total cash
- 46.36M
- Total debt
- 121.01M
- Return on equity
- -125.59%
- Short % of float
- 0.50%
- 50-day average
- 0.24794
- 200-day average
- 0.5979
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.18 | — | — |
| Aug 13, 2024 | Jun 1, 2024 | -0.10 | -0.17 | -0.07 | -70.00% |
| May 14, 2024 | Mar 1, 2024 | -0.12 | -0.22 | -0.10 | -83.33% |
| Mar 27, 2024 | Dec 1, 2023 | -0.11 | -0.21 | -0.10 | -90.91% |
| Nov 8, 2023 | Sep 1, 2023 | -0.13 | -0.19 | -0.06 | -46.15% |
| Aug 8, 2023 | Jun 1, 2023 | -0.17 | -0.19 | -0.02 | -11.76% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 16, 2023 | Guggenheim | main | — | Buy |
| Mar 20, 2023 | Guggenheim | main | — | Neutral |
| Nov 11, 2022 | Guggenheim | main | — | Buy |
| Aug 15, 2022 | Jefferies | init | — | Buy |
About The Oncology Institute, Inc.
The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Country
- United States
- Website
- theoncologyinstitute.com
News
BlackRock Inc. Buys Shares of 4,749,030 The Oncology Institute, Inc. $TOI 
Head to Head Contrast: RadNet (NASDAQ:RDNT) and Oncology Institute (NASDAQ:TOI) 
Oncology Institute Q2 Earnings Call Highlights 
The Oncology Institute Rebrands as Starling Oncology 
The Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference Call 
Best Cheap Stocks Under $10 to Buy Now in July 
The Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving Liquidity 
2 More Stocks to Buy for the AI Convergence 
The Oncology Institute (TOI) Soars 5.3%: Is Further Upside Left in the Stock? 
3 Stocks to Buy for the AI Convergence
Your note
Sign in to keep a note on TOI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARASCH RICHARD A | Director | Stock Award(Grant) | Nov 21, 2024 | 417,193 |
| HIVELY BRAD | Director | Purchase | Dec 1, 2024 | 666,753 |
| JOHNSON KAREN MARIE | Director | Stock Award(Grant) | Nov 21, 2024 | 167,185 |
| KAUSHAL MOHIT | Director | Stock Award(Grant) | Nov 21, 2024 | 177,253 |
| LING GABRIEL | Director | Stock Award(Grant) | Nov 21, 2024 | 109,057 |
| MCGEORGE ANNE | Director | Stock Award(Grant) | Nov 21, 2024 | 183,346 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 6.29% | 4,749,900 | 969.45K | Sep 29, 2024 |
| Deerfield Management Company, L.P. (Series C) | 4.45% | 3,360,052 | 685.79K | Sep 29, 2024 |
| TIFF Advisory Services, Inc. | 3.48% | 2,632,885 | 537.37K | Sep 29, 2024 |
| Cincinnati Insurance Company | 2.69% | 2,034,045 | 415.15K | Sep 29, 2024 |
| Kent Lake PR LLC | 2.65% | 2,000,000 | 408.20K | Sep 29, 2024 |
| Vanguard Group Inc | 2.36% | 1,783,454 | 364.00K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Growth Company Fund | 2.38% | 1,799,480 | 367.27K | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 1.69% | 1,273,384 | 259.90K | Sep 29, 2024 |
| Fidelity Growth Company K6 Fund | 0.57% | 431,188 | 88.00K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.56% | 422,983 | 86.33K | Sep 29, 2024 |
| Fidelity Series Growth Company Fund | 0.50% | 377,375 | 77.02K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.25% | 192,244 | 39.24K | Oct 30, 2024 |